Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORC
2026
Orchid Island Capital
ORC
$1.33B
| $3.02M | ﹤0.01% |
+61,200
| New | +$3.16M |
|
2027
Teledyne Technologies
TDY
$31.5B
| $3.01M | ﹤0.01% |
+23,600
| New | +$3.06M |
|
2028
Veracyte
VCYT
$3.32B
| $3.01M | ﹤0.01% |
361,400
-41,200
| -10% | -$336K |
|
|
ECOM
2029
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $3.01M | ﹤0.01% |
260,500
+22,424
| +9% | +$260K |
|
2030
Republic Bancorp
RBCAA
$1.92B
| $3M | ﹤0.01% |
84,100
+3,600
| +4% | +$126K |
|
|
PLPM
2031
DELISTED
Planet Payment, Inc
PLPM
| $3M | ﹤0.01% |
909,600
+75,200
| +9% | +$285K |
|
2032
Consolidated Water Co
CWCO
$500M
| $3M | ﹤0.01% |
241,900
-59,800
| -20% | -$712K |
|
|
ALBO
2033
DELISTED
Albireo Pharma Inc
ALBO
| $3M | ﹤0.01% |
145,432
-4,200
| -3% | -$86.2K |
|
2034
Urban One Class D
UONEK
$23.4M
| $2.99M | ﹤0.01% |
132,790
+499
| +0.4% | +$12.5K |
|
2035
James Hardie Industries
JHX
$18B
| $2.98M | ﹤0.01% |
189,000
+7,100
| +4% | +$112K |
|
2036
Assembly Biosciences
ASMB
$653M
| $2.97M | ﹤0.01% |
11,992
+11,200
| +1,414% | +$3.15M |
|
|
BHR
2037
Braemar Hotels & Resorts
BHR
$139M
| $2.97M | ﹤0.01% |
291,116
+201,505
| +225% | +$2.06M |
|
|
BCPC
2038
Balchem Corp
BCPC
$5.69B
| $2.96M | ﹤0.01% |
+38,100
| New | +$3.04M |
|
|
CXDC
2039
DELISTED
China XD Plastics Company Limited
CXDC
| $2.95M | ﹤0.01% |
627,700
+1,741
| +0.3% | +$8.27K |
|
2040
Installed Building Products
IBP
$6.39B
| $2.95M | ﹤0.01% |
55,699
+4,499
| +9% | +$232K |
|
|
UMH
2041
UMH Properties
UMH
$1.4B
| $2.95M | ﹤0.01% |
+172,991
| New | +$2.85M |
|
|
ACHN
2042
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.94M | ﹤0.01% |
641,300
-178,600
| -22% | -$718K |
|
2043
iShares MSCI Emerging Markets ETF
EEM
$30.5B
| $2.94M | ﹤0.01% |
71,100
-261,000
| -79% | -$10.6M |
|
|
ENV
2044
DELISTED
ENVESTNET, INC.
ENV
| $2.94M | ﹤0.01% |
74,192
+11,700
| +19% | +$421K |
|
|
SCX
2045
DELISTED
The L.S. Starrett Company
SCX
| $2.93M | ﹤0.01% |
341,000
+1,900
| +0.6% | +$17.7K |
|
|
HCCI
2046
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $2.93M | ﹤0.01% |
184,400
+34,000
| +23% | +$518K |
|
|
HNP
2047
DELISTED
Huaneng Power Intl, Inc.
HNP
| $2.92M | ﹤0.01% |
104,900
-65,600
| -38% | -$1.88M |
|
|
RVNC
2048
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.91M | ﹤0.01% |
+110,373
| New | +$2.46M |
|
|
TLRA
2049
DELISTED
Telaria, Inc.
TLRA
| $2.91M | ﹤0.01% |
1,167,900
+124,700
| +12% | +$285K |
|
2050
Diana Shipping
DSX
$309M
| $2.9M | ﹤0.01% |
1,023,541
-223,988
| -18% | -$651K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.